* patients with past medical history or current clinically significant concomitant diseases; * history of malignancies within 5 years. * receiving any prescription drugs or over-the-counter drugs, including herbal remedies, vitamins, and dietary supplements, within 14 days prior to screening. * participating in any clinical trial with drug intervention within 3 months prior to screening, or the drug is within the elimination phase (5 elimination half-lives), whichever is longer. * receiving any therapeutic or investigational biologic within 6 months prior to screening. * with a history of drug abuse within 1 year, or a positive result at screening. * females who are pregnant or lactating. * any other condition that the investigator deems inappropriate to participate in the trial, such as subject's mental or legal incapacity, potential compliance problems, and failure to complete the study-related procedures according to the requirements of the protocol, as determined by the investigator.

* patients with past medical history or current clinically significant concomitant diseases; * history of malignancies within 5 years. * receiving any prescription drugs or over-the-counter drugs, including herbal remedies, vitamins, and dietary supplements, within 14 days prior to screening. * participating in any clinical trial with drug intervention within 3 months prior to screening, or the drug is within the elimination phase (5 elimination half-lives), whichever is longer. * receiving any therapeutic or investigational biologic within 6 months prior to screening. * with a history of drug abuse within 1 year, or a positive result at screening. * females who are pregnant or lactating. * any other condition that the investigator deems inappropriate to participate in the trial, such as subject's mental or legal incapacity, potential compliance problems, and failure to complete the study-related procedures according to the requirements of the protocol, as determined by the investigator.

patients with past medical history or current clinically significant concomitant diseases; history of malignancies within 5 years. receiving any prescription drugs or over-the-counter drugs, including herbal remedies, vitamins, and dietary supplements, within 14 days prior to screening. participating in any clinical trial with drug intervention within 3 months prior to screening, or the drug is within the elimination phase (5 elimination half-lives), whichever is longer. receiving any therapeutic or investigational biologic within 6 months prior to screening. with a history of drug abuse within 1 year, or a positive result at screening. females who are pregnant or lactating. any other condition that the investigator deems inappropriate to participate in the trial, such as subject's mental or legal incapacity, potential compliance problems, and failure to complete the study-related procedures according to the requirements of the protocol, as determined by the investigator.

patients with past medical history or current clinically significant concomitant diseases; history of malignancies within 5 years. receiving any prescription drugs or over-the-counter drugs, including herbal remedies, vitamins, and dietary supplements, within 14 days prior to screening. participating in any clinical trial with drug intervention within 3 months prior to screening, or the drug is within the elimination phase (5 elimination half-lives), whichever is longer. receiving any therapeutic or investigational biologic within 6 months prior to screening. with a history of drug abuse within 1 year, or a positive result at screening. females who are pregnant or lactating. any other condition that the investigator deems inappropriate to participate in the trial, such as subject's mental or legal incapacity, potential compliance problems, and failure to complete the study-related procedures according to the requirements of the protocol, as determined by the investigator.